In new research, Travis Dunckley, Ph.D., a researcher at Arizona State University's Biodesign Institute, examines genetic modifications associated with the development of PD and PD-associated dementia, bringing new investigative tools to bear.
A biosensor developed by researchers at the National Nanotechnology Laboratory in Campinas, Brazil, has been proven capable of detecting molecules associated with neurodegenerative diseases and some types of cancer. The device is a single-layer organic nanometer-scale transistor on a glass slide. It contains the reduced form of the peptide glutathione, which reacts in a specific way when it comes into contact with the enzyme glutathione S-transferase, linked to Parkinson's, Alzheimer's and breast cancer, among other diseases.
In a recent retrospective analysis, investigators discovered that the year-on-year increase in rigidity found in Parkinson's disease flattened off with the regular use of laxatives to manage constipation.
For decades, scientists have fiercely debated whether rapid eye movement sleep -- the phase where dreams appear -- is directly involved in memory formation. Now, a study published in Science by researchers at the Douglas Mental Health University Institute (McGill University) and the University of Bern provides evidence that REM sleep does, indeed, play this role -- at least in mice.
University of Adelaide researchers have developed a new theory for the causes of dementia and other neurodegenerative diseases, involving an out-of-control immune system.
Researchers at Lund University in Sweden have used a completely new preclinical technique and analysis of tissue from patients to show exactly what happens when certain patients with Parkinson's disease are restored as a result of nerve cell transplants. They have also identified what makes many of the transplant patients develop serious side effects in the form of involuntary movements.
Computer simulations of disease processes and detailed digital models of our organs could provide more accurate monitoring and outcome measurements for clinical trials, according to research being presented in Sheffield today.
In the late 1980s and over the 1990s, researchers at Lund University in Sweden pioneered the transplantation of new nerve cells into the brains of patients with Parkinson's disease. The outcomes proved for the first time that transplanted nerve cells can survive and function in the diseased human brain. Some patients showed marked improvement after the transplantation while others showed moderate or no relief of symptoms. A small number of patients suffered unwanted side-effects in the form of involuntary movements.
University of Alabama at Birmingham researchers report the first documentation that suppressing a key cell-signaling pathway in a rat model of Parkinson's disease reduces pathogenesis. Oral administration of AZD1480 -- one of the JAK/STAT pathway inhibitors generally known as Jakinibs -- lessened the destructive inflammation and nerve cell degradation in the area of the brain affected by Parkinson's.
Researchers have obtained images of the NMDA receptor in active, non-active, and inhibited states. Understanding how NMDA receptors activate is critical in designing novel therapeutic compounds for schizophrenia, depression, Alzheimer's and other illnesses.